Biosimilars Could Cut Spending for Biologic Therapy in the US
Increased market growth of biosimilars that are similar to brand-name biologic agents has the potential to reduce spending on prescription drugs
Breast Cancer
Enobosarm Gets Fast Track Status for AR+ER+HER2- Metastatic Breast Cancer
Enobosarm is an oral, first-in-class, selective androgen receptor agonist.
BRCA2 Linked to Inferior Outcomes of Treatment With CDK4/6 Inhibitors Plus Endocrine Therapy
An analysis of germline-somatic interactions in breast cancer tumors revealed novel associations relevant to the disease’s progression and treatment resistance. For example, the study presented at the 2021 San Antonio Breast Cancer Symposium (SABCS) showed that carriers of the BRCA2 mutation had inferior outcomes to treatment with first-line CDK4/6 inhibitors plus endocrine therapy. This could…
ctDNA Promising Biomarker in Ribociclib, Letrozole-Treated HR+/HER2- Advanced Breast Cancer
Liquid biopsies were used to determine whether ctDNA analysis was predictive of disease progression in women with HR+/HER2- breast cancer.
Samuraciclib Plus Fulvestrant Demonstrates Antitumor Activity in Advanced Breast Cancer
A single-arm cohort study sought to determine the efficacy of adding samuraciclib to treatment for ER-positive and/or PGR-positive, HER2-negative breast cancer.
Surgical Staging Affects Some QOL Scores in Early Breast Cancer
An analysis of patients in the INSEMA trial sought to determine the impact of no SLNB vs SLNB and SLNB alone vs SLNB with ALND on quality of life for patients with breast cancer.
Breast Cancer-Related Lymphedema More Common Among Black Women
A prospective study sought to determine the significance of race on the risk of developing lymphedema and disease severity in women with breast cancer.
Monitoring ESR1 Mutations May Optimize Treatment in Metastatic Breast Cancer
Monitoring bESR1mut enabled optimization of the endocrine therapy used with a CDK4/6 inhibitor.
Trastuzumab Deruxtecan Improved PFS Across HER2+ Breast Cancer Subgroups
Researchers presented updated findings from the DESTINY-Breast03 trial.
Outcomes in Inflammatory Breast Cancer Improved With Modern Treatment
An analysis evaluated outcomes for patients with breast cancer who were treated with a modern approach compared with a historical standard approach.
